Fundamental Data for MLNM

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company''s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates.

# Employees: 966

Address: ,,,

Phone:

Fax:

Website:

Email:

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Deborah Dunsire (Presi.; C.E.O.)

Marsha H. Fanucci (Sr. V.P.; C.F.O.)

Anna Protopapas (Sr. V.P.; Corp. Development)

Laurie B. Keating (Sr. V.P.; General Counsel)

Stephen M. Gansler (Sr. V.P.; Human Resources,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 12/31/2007

Next Earnings Date(Expected): 4/24/2008

Mean EPS (Next Qtr): $0.05

Mean EPS (Year): $0.24

Mean Estimate(Long Term): $30.00

P/E Ratio(Based on EPS estimate): 103.710

Number of Estimates: 13

Shares Performance

Period	MLNM	Compare to S&P
YTD	66.69 %	76.23 %
4 Weeks	1.88 %	-1.30 %
12 Weeks	81.73 %	75.46 %

Shares Information

Analyst Coverage: Y

Avg Volume: 11762396

Shares Outstanding: 324M

Market Cap: $8.11B

52 Week High: $24.97

52 Week Low: $9.66

P/E Ratio: 192.080

PEG Ratio: 3.460

Split: On 10/5/2000 MLNM split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 1,400.00 %

EPS Growth in Last Year: 333.33 %

Sales Growth in Last Quarter: -23.04 %

Sales Growth in Last Quarter: 25.94 %

Financials

Qtr Book Value: $3.58

Cash Flow/Share: $78.21

Change in Payout Ratio: -0.010

Price/Sales: 14.580